BioSpace News Archive

Accuray Incorporated (NASDAQ: ARAY) – Thailand’s Lopburi Cancer Hospital, a center of excellence for cancer treatment, is the first in the Asia-Pacific region to clinically use the combination of RaySearch’s treatment planning system RayStation® with Accuray’s Radixact® Treatment Delivery System.

VITAS® Healthcare, the nation’s leading provider of end-of-life care, has named Rory Farrand as director of VITAS® Palliative Care.

Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that four new members have been appointed to the Board of Directors effective immediately.

New analyses from Phase 3 REGENERATE study evaluating the effects of OCA on non-invasive liver fibrosis tests and NASH patient-reported outcomes

Initial Purchase of $1 Million of Salarius Shares Completed, Aspire Capital to Purchase Additional Salarius Common Stock over a 30-Month Span Extending into 2022

Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the results of a Phase 2 study of NYX-2925 in patients with fibromyalgia have been selected for a late-breaking poster presentation at the American College of Rheumatology Annual Meeting

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, reports financial results for the third quarter of 2019 and provides an update on the Company’s recent developments.

Theragun, Inc., the leader in hand-held percussive therapy devices, has entered into a comprehensive partnership with Life Time, the nation’s premier healthy lifestyle brand.

Nuvation Bio, Inc., a stealth biotechnology company developing proprietary therapies focused on oncology, announces the closing of $275 million in an oversubscribed Series A financing.

Microbion Corporation of Bozeman, MT, and Microbion Pharma Corp. of Vancouver, BC (“Microbion”) today announced results from a Phase 1b trial of its novel microbial bioenergetic inhibitior, pravibismane, in patients with moderate to severe infected diabetic foot ulcers.